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Abstract   
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder with unclear etiology. 
Cognitive impairment in AD might be associated with altered serotonergic system. The aim of 
the study was to determine platelet serotonin (5-HT) concentrations and platelet monoamine 
oxidase type B (MAO-B) activity in patients with different severity of AD. Platelet 5-HT 
concentrations and MAO-B activity were determined spectrofluorimetrically in 74 female 
patients with AD (NINCDS-ADRDA, DSM-IV-TR criteria), subdivided according to the 
Mini Mental State Examination (MMSE) scores in three groups with a) 23 patients in early 
(MMSE scores 19-24), b) 23 patients in middle (MMSE 10-18), and c) 28 patients in late 
(MMSE 0-9) phase of AD, and in 49 age-matched healthy women. Platelet 5-HT 
concentrations and MAO-B activity were similar between all patients with AD and healthy 
subjects, but were significantly lower in patients in the late phase of AD than in other phases 
of AD, and in healthy controls. The significant correlations were found between MMSE 
scores and platelet 5-HT concentrations, MAO-B activity and age. Lower platelet 5-HT 
concentration and MAO-B activity in the late phase of AD suggested that these markers might 
indicate severity and/or clinical progress of AD. 
 
Key words:  Alzheimer’s disease, blood platelets, monoamine oxidase type B, phase of 
Alzheimer’s disease,  serotonin  
 
Abbreviations: AD, Alzheimer’s disease; ANOVA, One Way Analysis of Variance; HPLC, 
high pressure liquid chromatography;  MAO, monoamine oxidase; MMSE, Mini Mental State 
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1. Introduction  
 
 Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, 
with still unclear aetiology (Forsyth and Ritzline, 1998). The neurobiological background of 
AD includes the accumulation of amyloid plaques and neurofibrillary tangles in the brain, and 
dysfunction in the cholinergic function (Pakaski and Kalman, 2008). The alterations in the 
other neurotransmitter systems, especially serotonergic and dopaminergic, are also thought to 
be responsible for the cognitive deficits and the behavioral disturbances observed in patients 
with AD (Garcia-Alloza et al. 2005; Terry et al. 2008).   
 Serotonin (5-hydroxytryptamine, 5-HT) has an important role in the regulation of the 
synaptic function, neurite outgrowth, synaptogenesis and cell survival (Terry et al. 2008). It 
regulates different physiological functions (circadian rhythm, food intake, locomotion, 
thermoregulation, nociception, sexual activity), behaviors (Lucki, 1998), and cognitive 
functions such as learning and memory (Mattson et al. 2004). The decrease in the brain 
concentration of 5-HT and its main metabolites 5-hydroxyindoleacetic acid, the loss of 
serotonergic 5-HT1A receptors in the hippocampus and nuclei raphe (Kepe et al. 2006), and 
5-HT2 receptors in cerebral cortex (Blin et al. 1993) were found in patients with AD. Genetic 
investigations suggested the role of serotonergic 5-HT2A and 5-HT2C receptors 
polymorphisms in the development of behavioral and psychological symptoms of AD 
(Pritchard et al. 2008). Recently, a beneficial effect of the additional treatment with selective 
5-HT reuptake inhibitor, fluoxetine, on daily living and functioning was found in AD patients 
treated with rivastigmine (Mowla et al. 2007).  
 Blood platelets have been proposed as an easy obtainable limited peripheral model for 
some processes in the presynaptic (5-HT reuptake, monoamine oxidase type B /MAO-B/ 
activity) and postsynaptic (5-HT2A receptors binding) parts of the central serotonergic 
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neurons (Camacho and Dimsdale, 2000; Mendelson, 2000), and for the expression of the 
brain amyloid precursor protein (Cattabeni et al. 2004). The studies on platelet 5-HT 
concentration and platelet MAO-B activity in AD yielded inconsistent results. The increased 
(Meszaros et al. 1998), decreased Kumar et al. 1995) or unaltered (Mimica et al. 2005) 
platelet 5-HT concentrations, as well as increased (Adolfsson et al. 1980) or unaltered 
(Ahlskog et al. 1996) platelet MAO-B activity were observed in AD. Our recent studies 
showed that platelet MAO-B activity might be used as a biomarker for the presence of 
psychotic features in AD (Mimica et al. 2008), and for the early or late onset AD (Mimica et 
al. 2005).  
 Platelet 5-HT concentration (Mueller-Orlinhausen et al. 2004) and platelet MAO-B 
activity (Oreland, 2004) were found to be altered in different psychopathologies, behaviors, 
personality traits and particular neuro-psychiatric symptoms. In addition, platelet MAO-B 
activity is assumed to represent a biological marker for central 5-HT activity (Fahlke et al. 
2002; Oreland, 2004). Therefore, the hypothesis of the present study was that these platelet 
biochemical markers would correlate with the cognitive indices of severity in AD. As both 
markers, platelet 5-HT concentration (Muck-Seler et al, 1996, 1999) and platelet MAO-B 
activity (Mimica et al. 2005; Pivac et al. 2005) are under influence of sex, and platelet MAO-
B activity is affected by smoking (Oreland, 2004; Pivac et al. 2006a), the study included only 
female non-smoking subjects. The aim of the study was to determine platelet 5-HT 
concentrations and platelet MAO-B activity in patients with probable AD and control 
subjects, and in patients subdivided according to the severity of dementia into groups of 
patients in early, middle and late phase of AD. 
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2. Methods 
2.1. Subjects 
The study included 74 female patients with AD (mean age ± SD, 76.9 ± 9.9 years, range 
53-96 years). All AD patients met the diagnostic criteria of probable AD according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (APA, 2000) and the 
criteria of the National Institute of Neurologic and Communicative Disorders and Stroke and 
the Alzheimer‘s Disease and Related Disorders Association (NINDS-ADRDA; McKhann et 
al. 1984). The exclusion criteria for all patients were diagnoses of severe organic disease 
(cancer, heart disease, epilepsy, brain trauma), major functional psychiatric disorders 
(depression schizophrenia, mania), smoking, alcoholism and treatment with any medication 
known to influence platelet 5-HT concentration (selective serotonin reuptake inhibitors, 
tricyclic antidepressants) or platelet MAO-B activity (selegiline, iproniazid, tranylcypromine, 
vitamine B12). Patients were treated with acetylcholinesterase inhibitors like donepezil and 
memantine, but were medication-free for at least 1 week before blood sampling. The severity 
of dementia was assessed by Mini Mental Status Examination (MMSE; Folstein et al. 1975). 
The mean MMSE scores in all patients with AD were 11.7 ± 8.1. Patients were subdivided 
according to the MMSE scores into three groups: a) 23 patients in the early (MMSE 19-24) 
phase of AD, b) 23 patients in the middle (MMSE 10-18) phase of AD and c) 28 patients in 
the late (MMSE 0-9) phase of AD. MMSE was translated and validated to Croatian 
population. The permission and licensing are available on www.parinc.com.  
Control group consisted of 49 carefully age- and sex- matched healthy older adults 
(mean age ± SD, 73.7 ± 8.8 years, range 56-89 years), recruited from the local senior centers. 
They were evaluated with a clinical interview to rule out for Axis I disorders, current and past 
medical status, and MMSE. Exclusion criteria were psychotropic medication mentioned 
above, MMSE less than 26 (indicating possible dementia) or any Axis I disorder. 
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Participants or their guardians gave informed consent. The study design was approved 
by the local Ethics Committee. The study has been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki.  
 
 2.2. Biochemical analysis 
 Blood samples (8 ml) were taken during routine laboratory tests from a jugular vein, 
after an overnight fasting, in a plastic syringe with 2 ml of acid citrate dextrose anticoagulant. 
Platelet rich plasma (PRP) was obtained after centrifugation of whole blood, and platelets 
were sedimented by further centrifugation of PRP. Platelet 5-HT concentration was 
determined by the spectrofluorimetric method, as previously described Muck-Seler et al. 
(1999), using Varian Cary Eclipse spectrofluorimeter. Platelet MAO-B activity was determined 
using kynuramine as a substrate by modification of the method of Krajl (1965), as previously 
described (Muck-Seler et al. 2002). Platelet protein levels were measured by the 
spectrofotometric method (Lowry et al. 1951). All biochemical determinations were performed 
by laboratory personnel who were blind to diagnosis. 
 
 2.3. Statistical analysis 
The results were expressed as means ± standard deviations (SD). Due to the failed 
normality of the data, statistical evaluation was done using Kruskal–Wallis one-way analysis 
of variance (ANOVA) by ranks, followed by Mann-Whitney rank sum test for pair-wise 
comparisons. The Spearman Rank Order Correlation was used to assess the coefficient of 
correlation between age or MMSE scores and/or biochemical parameters. The significance 
was set to p values less than 0.05. The statistical analysis of the data was conducted with 
SigmaStat 3.1. (Jandell Scientific Corp., San Raphael, California, USA). 
 
 8
3. Results 
 
Age of the patients with AD and control group did not differ significantly (P=0.066, 
Mann-Whitney t-test). There was a significant difference (H=16.0, df=2, P<0.001, Kruskal-
Wallis ANOVA) in age between patients with AD subdivided according to the different phases 
of the disease.  Mann-Whitney test showed that patients with AD in the late phase of AD were 
significantly (P<0.001) older than patients in the early and middle phase of disease, while 
patients in the middle phase of AD were significantly (P<0.001) older than patients in early 
phase of AD (Table 1).    
As expected,  MMSE scores (mean age ± SD) were significantly different (P<0.001, 
Mann-Whitney test) between control women (28.56 ± 1.94, range 26-30) and patients with 
AD (11.69 ± 8.14, range 1-24). The expected, significant (P<0.001, Mann-Whitney test) 
decline in the severity of dementia in AD was found in patients in different phases of AD, with 
the highest MMSE scores in early phase of AD and the lowest in the late phase of AD (Table 1). 
 Platelet 5-HT concentration (nmol/mg protein) was similar (P=0.697, Mann-Whitney 
test) in control women (0.81 ± 0.34) and all patients with AD (0.84 ± 0.43). When patients 
with AD were subdivided according to the different phases of AD, their platelet 5-HT 
concentration was significantly different (H=10.5, df=2; P=0.005, Kruskal-Wallis ANOVA). 
Mann-Whitney test revealed that patients in the late phase of AD had significantly lower platelet 
5-HT concentration than healthy controls (P=0.015), and than patients in the early (P<0.011), or 
middle (P=0.012) phase of AD (Fig 1). 
 Platelet MAO-B activity (nmol 4OHQ/mg protein/h) did not differ significantly 
(P=0.568) between control women (30.64 ± 12.18) and all patients with AD (29.11 ± 11.69). 
Between patients in the early, middle and late phase of AD, platelet MAO-B activity was 
significantly different (H=9.08, df=2, P=0.011, Kruskal-Wallis ANOVA), as patients in the late 
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phase of AD had significantly (Mann-Whitney test) lower platelet MAO-B activity than healthy 
controls (P=0.038), than patients in the early phase of AD (P=0.003), and than patients in middle 
(P=0.033) phase of AD (Fig 2). 
 A significant positive correlation (Spearman’s correlation) was found between MMSE 
scores and platelet 5-HT concentration (r=0.299, P=0.009), or MMSE scores and platelet 
MAO-B activity (r=0.327, P=0.005) in patients with AD. There was a significant (r= -0.460, 
P=0.000) negative correlation between age and MMSE scores in patients with AD, or 
between MMSE scores and age in control subjects (r=-0.568, P=0.000).  
 No significant correlation was observed between age and platelet 5-HT concentration 
(r=0.008, P=0.945), or age and platelet MAO-B activity (r=-0.162, P=0.168) in patients with 
AD, or between age and platelet 5-HT concentration (r=0.012, P=0.941), age and platelet 
MAO-B activity (r=-0.012, P=0.943), MMSE scores and platelet 5-HT concentration (r=-
0.192, P=0.241), or MMSE scores and platelet MAO-B activity (r=0.153, P=0.351) in control  
subjects. 
 
4. Discussion 
 
 The most important findings of the present study were 1) similar values of platelet 5-
HT concentration or platelet MAO-B activity between all patients with AD and sex- and age- 
matched control subjects; and 2) significant relationship between the severity of dementia in 
AD and platelet 5-HT concentration and platelet MAO-B activity in female patients in the 
early, middle and late phase of AD. To the best of our knowledge, this is the first report of the 
significantly lower platelet 5-HT concentration and reduced platelet MAO-B activity in 
patients in the late phase of AD compared to patients in the early phase of AD.  
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 In the present study we have found similar platelet 5-HT concentrations between 
patients with AD as a group and control subjects. This finding is in agreement with alike 
platelet 5-HT concentrations in patients with early or late onset AD (Mimica et al. 2005), but 
in contrast with decreased platelet 5-HT concentration in patients with AD (Kumar et al. 
1995), and increased platelet 5-HT concentrations in demented patients with delusions 
(Meszaros et al. 1998) compared to 5-HT values in healthy controls. The explanation for the 
discrepancies between studies should be sought in different diagnoses (AD vs. dementia) and 
presence of delusions ((Meszaros et al. 1998), which were reported to increase platelet 5-HT 
concentration (Pivac et al. 2006b). In addition, previous studies (Kumar et al. 1995; Meszaros 
et al. 1998) included smaller number of patients and control subjects, the severity of AD was 
not specified, and different methods i.e. fluorimetric (Mimica et al. 2005) or HPLC  (Kumar 
et al. 1995; Meszaros et al. 1998) were used for the determination of platelet 5-HT 
concentrations.  
 The most important finding of the presents study is a significantly different platelet 5-
HT concentration in patients with AD subdivided according to cognitive impairment. A 
pronounced decrease in platelet 5-HT concentrations was found in the late stage of AD 
compared to platelet 5-HT values in the other phases of disease and to values in healthy 
controls. It is noteworthy that in agreement with our previous study (Mimica et al. 2005) 
platelet 5-HT concentrations in patients with early and middle phase did not differ from the 5-
HT values in healthy controls.  
 The reasons leading to the alterations of platelet 5-HT in different phases of AD are 
still unknown. The reduced 5-HT concentration in the present and previous (Mimica et al. 
2008) study in platelets, CSF (Tohgi et al. 1992) and brain (Garcia-Alloza et al. 2005) of 
patients in the late phase of AD would suggest the decrease in 5-HT synthesis. The main 
factors that influence 5-HT synthesis are plasma availability of its precursor tryptophan, and 
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the activity of the rate-limiting enzyme tryptophan hydroxylase (TPH). Since tryptophan is an 
essential amino acid, its plasma levels depend on the dietary intake and eating pattern that 
might occasionally be altered in AD (Ikeda et al. 2007). The literature data on tryptophan 
concentrations in body fluids and brain of patients with AD are inconsistent. The majority of 
studies have found low tryptophan concentrations in serum (Widner et al. 2000), plasma 
(Fekkes et al. 1998) and CSF (Tohgi et al. 1992)  while other studies showed no alterations in 
tryptophan concentrations in plasma (Fonteh et al. 2007) and brain (Storga et al. 1996) in 
patients with AD. Low plasma tryptophan concentration might be also a consequence of the 
enhanced tryptophan degradation via the kynuramine pathway (Widner et al. 2000), since a 
dysregulation of both serotonergic and kynuramine pathways of tryptophan metabolism have 
been associated with pathophysiology of AD (Ruddick et al. 2006). In addition, the decline in 
the cognitive performance was observed after tryptophan depletion in healthy volunteers 
(Park et al. 1994), patients with AD (Porter et al. 2000) and patients with mild to moderate 
AD (Newhouse et al. 2002), confirming the role of 5-HT system in behavioral and cognitive 
changes in AD. 
 The TPH is a specific iron-containing enzyme involved in the biosynthesis of 5-HT. 
Reduced TPH activity was found in some brain areas of patients with AD (Gottfries, 1990) 
that might be associated with a decrease in 5-HT synthesis (Garcia-Alloza et al. 2005). It has 
been shown that tetrahydrobiopterin and folic acid are two cofactors necessary for TPH 
activity. The lack of the tetrahydrobiopterin in AD patients could alter THP activity and 
consequently decrease 5-HT synthesis. As a cofactor for nitric oxide synthase (Foxton et al. 
2007), tetrahydrobiopterin is also involved in the production of free radicals within the cell. 
Since TPH activity is sensitive to reactive oxygen species, the tetrahydrobiopterin deficiency 
could also impair 5-HT synthesis through oxidative damage of TPH (Cash, 1998).  
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 Since platelets do not synthesize 5-HT, their 5-HT concentrations depend on the 5-HT 
synthesis in the enterocromaffine cells of the gut, and on 5-HT active transport throughout the 
platelet membrane. Our results showing a reduced platelet 5-HT concentration in patients with 
AD, with most severe symptoms, compared to platelet 5-HT concentration in patients with the 
mild or moderate symptoms, might be a consequence of the different 5-HT uptake among 
groups. Although in the present study we did not determine platelet 5-HT uptake, several 
studies (Arora et al. 1991; Koren et al. 1993) have found reduced 5-HT uptake, expressed as a 
decrease in maximum number (Vmax) of 5-HT uptake sites in patients with AD compared to 
values in healthy control subjects. Since significantly lower 5-HT uptake or reduced Vmax 
were found in severely ill patients with AD compared to both, patients with mild AD, and to 
healthy controls (Arora et al. 1991), decreased platelet 5-HT concentration observed in our 
patients in the late phase of AD might be related to a reduced 5-HT uptake. Platelet 5-HT 
uptake depends on 5-HT transporter and 5-HT transporter (5-HTT) gene. However, a 
relationship between the changes in 5-HT uptake and 5-HTT gene is not clear, since no 
difference in the allelic distribution on the deletion/insertion polymorphism of the 5-HTT gene 
between patients with AD and non-demented controls (Zill et al. 2000), or a relationship 
between long allele of the 5-HTT gene and development of aggressive behavior in AD 
(Sukonick et al. 2001), was reported.  
  To avoid the complex gender-related differences observed in the clinical presentation 
(Grossi et al. 2005) and cognitive deficits (McPherson et al. 1999) in AD, and gender related 
difference in platelet 5-HT concentrations (Muck-Seler et al. 1996, 1999), in platelet MAO-B 
activity (Muck.Seler et al. 1991; Pivac et al. 2005), and in the rate of 5-HT synthesis in the 
brain (Nishizawa et al. 1997), the present study included only female patients with AD and 
control women. 
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 It has been shown that CSF biomarkers of AD (beta-amyloid 1–42, total tau and tau 
phosphorylated at threonine 181) differ according to age, suggesting that AD pathology might 
differ between young and old patients (Bouwman et al. 2008, Meltzer et al. 1998). In our 
study patients and controls were matched for age and the age range was similar for all groups. 
Although the patients in the late stage of disease were the oldest, there was no significant 
correlation between age and platelet 5-HT concentrations, suggesting no influence of aging on 
platelet 5-HT values. In contrast to our results, a positive correlation between age and platelet 
5-HT concentration, and increased platelet 5-HT concentration in older patients with dementia 
was found (Meszaros et al. 1998).  
We have found similar platelet MAO-B activity between all patients with AD and 
corresponding control subjects. Previously it has been reported that platelet MAO-B activity 
was increased (Adolfsson et al. 1980; Mimica et al. 2005, 2008) or unaltered (Ahlskog et al. 
1996; Meszaros et al. 1998) in patients with AD or dementia compared to values in healthy 
controls. These discrepancies might be explained by the different diagnostic entities across 
studies i.e. AD vs. dementia (Meszaros et al. 1998), and in the fact that our earlier studies 
(Mimice et al. 2005, 2008) included small number of both male and female AD patients in 
early and middle phase of AD, and that platelet MAO-B activity was compared with enzyme 
activity in control subjects who were considerably younger than patients with AD.  
The results of the present study have shown significantly lower platelet MAO-B 
activity in patients in the late stage of AD compared to values in patients in the early and 
middle phase of AD and healthy controls, indicating a decline in platelet MAO-B activity 
associated to cognitive impairment in AD. The reduced platelet MAO-B activity in severely 
demented patients with AD agrees with the “MAO-B vulnerability hypothesis”, suggesting 
that platelet MAO-B activity is a genetic marker for the capacity of central 5-HT system 
(Oreland, 2004). The reason for the altered platelet MAO-B activity during the progress of 
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AD is at present unknown. There are several factors that might influence platelet MAO-B 
activity such as aging, sex, alcohol abuse, smoking, different medication and ethnicity 
(Oreland, 2004). Sex related difference in platelet MAO-B activity, i.e. higher enzyme 
activity in female than in male subjects, observed in healthy controls (Muck-Seler st al. 1991; 
Oreland, 2004; Pivac et al. 2005) were excluded since the present study included only female 
patients with AD and female control subjects. To avoid the possible effect of ethnicity or race 
(Sobell et al. 1997) on platelet MAO-B activity, the subjects in our study were ethnically 
uniform Caucasian of the Croatian origin. Psychotropic drugs like haloperidol (Meszaros et 
al. 1998), lithium (Oreland, 2004) or lamotrigine (Muck-Seler et al. 2008) were reported to 
increase platelet MAO activity, while antidepressant drug sertraline (Pivac et al. 2003), or 
vitamin B12 (Reglan et al. 1991) decreased platelet MAO-B activity. As our patients or 
control subjects did not receive haloperidol, lithium, lamotrigine, sertraline or vitamin B12, 
the possible effect of medication on platelet MAO-B activity could be excluded.  
The data on the effect of older age on platelet MAO-B activity are inconsistent.  
Increased (Meszaros et al. 1998; Nicotra et al. 2004) or unchanged (Pivac et al. 2006a) 
platelet MAO-B activity was found in healthy controls during aging. Since MAO is a 
mitochondrial enzyme, it is possible that altered MAO-B activity in AD might be a 
consequence of the changes in the structure of the mitochondrial membrane occurring during 
aging (Nicotra et al. 2004). As no significant correlation between age and platelet MAO-B 
activity was found in our patients with AD or control subjects, and our patients with AD had 
lower and not higher platelet MAO-B activity, age of the patients presumably did not 
influence reduced platelet MAO-B activity found in severely ill AD patients.  
It has been reported that lower platelet MAO-B activity might be induced by smoking 
(Oreland, 2004; Pivac et al. 2006a, 2007) and chronic alcohol abuse (Oreland, 2004). To 
exclude the effect of smoking, all female subjects included in the study were nonsmokers. 
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Regarding alcoholism, our (Pivac et al. 2005), as well as other (Anthenelli et al. 1998) data 
failed to find the lowering effect of chronic alcohol abuse on platelet MAO-B activity. In 
addition, platelet MAO-B activity did not differ between patients with dementia and patients 
with alcoholic dementia (Meszaros et al. 1998). Since our patients with the lowest platelet 
MAO-B activity were hospitalized and did not abuse alcohol in the controlled hospital 
environment, the possible lowering effect of alcohol on platelet MAO-B might be excluded. 
The reason for the alterations in platelet MAO-B during the progress of AD may be 
related to transcriptional changes in MAO-B protein and/or to changes in the cell milieu 
causing manipulation of the enzyme activity (Oreland, 2004). Platelet MAO-B activity might 
be affected by genetic factors (Oreland 2004). Polymorphism in intron 13 of MAO-B gene 
does not alter platelet MAO-B activity (Jansson et al. 2005; Pivac et al. 2005, 2007). 
However, two MAOA gene haplotypes in the MAOA gene (Jansson et al. 2005), as well as 
polymorphism on the promoter region of the 5-HTT gene (Paaver et al. 2007) were shown to 
be associated with lower platelet MAO activity.  
  We have found a positive correlation between MMSE scores and platelet 5-HT 
concentration, and MMSE scores and platelet MAO-B activity in AD patients. The results 
indicate that more severe AD symptoms are associated with reduced platelet 5-HT 
concentration and lower platelet MAO-B activity. The mild but significant positive 
correlation between MMSE scores and platelet MAO-B activity is in line with the association 
between enzyme activity and severity of AD (Bongioanni et al. 1996). MMSE scores, 
indicating severity of dementia, were significantly negatively correlated with age in both 
control subjects and patients with AD, indicating decline in cognitive functions associated 
with aging. 
 The limitations of the present study were that the results are restricted to changes of 
platelet serotonergic variables, and that dietary habits of patients were not controlled. Namely, 
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plasma levels of tryptophan are under influence of diet, and reduced intake of tryptophan 
would result in reduced platelet 5-HT concentration. Platelet MAO-B activity might be 
reduced after B12 therapy in patients with dementia of AD type (Reglan et al. 1991). In 
contrast to the uncontrolled dietary habits of the patients in early and middle stage of AD, 
patients in the late stage of AD, who had the lowest platelet 5-HT concentration, and reduced 
platelet MAO-B activity, were hospitalized, and fed with the balanced hospital diet, and 
therefore the influence of the diet might be excluded. The advantages of the study were in 
ethnically uniform Caucasian sample, matched patients in terms of race, age, gender, phase of 
AD, in detailed clinical assessment, in the inclusion of sex- and age-matched control group, 
and in determination of two biological markers. 
 
5. Conclusions  
 
We have found a positive correlation between MMSE scores and platelet 5-HT concentration, 
and MMSE scores and platelet MAO-B activity in AD patients. The results indicate that more 
severe AD symptoms are associated with reduced platelet 5-HT concentration and lower 
platelet MAO-B activity. The mild but significant positive correlation between MMSE scores 
and platelet MAO-B activity is in line with the association between enzyme activity and 
severity of AD (Bongioanni et al. 1996). MMSE scores, indicating severity of dementia, were 
significantly negatively correlated with age in both control subjects and patients with AD, 
indicating decline in cognitive functions associated with aging. 
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Legend to Figures  
 
Fig. 1.  Platelet serotonin (5-HT) concentrations in female patients with early, middle and late 
phase of the Alzheimer's disease (AD) and in healthy controls. Each column represents mean 
± SD. Number of subjects is given in parenthesis. 
* P <0.015 vs. healthy controls; ** P =0.012 vs. middle phase; *** P=0.011 vs. early phase of 
AD   (Kruskal Wallis ANOVA on ranks and Mann-Whitney t-test) 
 
 
Fig. 2.  Platelet monoamine oxidase type B (MAO-B) activity in female patients with early, 
middle and late phase of the Alzheimer's disease (AD) and in healthy controls. Each column 
represents mean ± SD. Number of subjects is given in parenthesis. 
* P =0.038 vs.healthy controls; ** P =0.033 vs. middle phase; *** P=0.003 vs. early stage of 
AD   (Kruskal Wallis ANOVA on ranks and Mann-Whitney t-test) 
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Table 1. Demographic data of patients with Alzheimer's disease (AD) in different stage of 
disease. Age and Mini Mental Status Examination (MMSE) are represent as mean ± SD.  
 
*P<0.037 vs. early phase; **P<0.015 vs. middle phase; ***P<0.001 vs. early phase;               
# P<0.001 vs. all other phases (Kruskal Wallis ANOVA on ranks and Mann-Whitney t-test)  
 
 
  
Patients with AD 
  
Early phase 
 
Middle phase 
 
Late phase 
 
Number of patients 
 
23 
 
23    
 
28 
 
Age (years) 
range 
 
70.9 ± 10.2 
59-91 
 
77.0 ± 8.8*  
56-91 
 
   82.0 ± 8.1**  *** 
57-96 
 
MMSE (scores) 
range 
 
20.8 ±  1.3 
19-24 
 
14.2 ± 2.3# 
10-18 
       
2.2 ± 1.9 # 
0-9 
